CL2013001565A1 - Metodo para tratar la ingesta excesiva o comer compulsivamente, que comprende el uso de bupropion y naltrexona y la composicion farmaceutica que comprende a ambos compuestos. - Google Patents

Metodo para tratar la ingesta excesiva o comer compulsivamente, que comprende el uso de bupropion y naltrexona y la composicion farmaceutica que comprende a ambos compuestos.

Info

Publication number: CL2013001565A1
Authority: CL; Chile
Prior art keywords: bupropion; naltrexone; compounds; pharmaceutical composition; excessive intake
Prior art date: 2010-12-03

Application number

CL2013001565A

Other languages

English (en)

Inventor

Eduardo Dunayevich

Susan Mcelroy

Ron Landbloom

Original Assignee

Orexigen Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2013-05-31

Publication date

2014-04-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001565(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-31 Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc

2014-04-04 Publication of CL2013001565A1 publication Critical patent/CL2013001565A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Plant Substances (AREA)

CL2013001565A 2010-12-03 2013-05-31 Metodo para tratar la ingesta excesiva o comer compulsivamente, que comprende el uso de bupropion y naltrexona y la composicion farmaceutica que comprende a ambos compuestos. CL2013001565A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41935410P	2010-12-03	2010-12-03

Publications (1)

Publication Number	Publication Date
CL2013001565A1 true CL2013001565A1 (es)	2014-04-04

Family

ID=46172302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001565A CL2013001565A1 (es)	2010-12-03	2013-05-31	Metodo para tratar la ingesta excesiva o comer compulsivamente, que comprende el uso de bupropion y naltrexona y la composicion farmaceutica que comprende a ambos compuestos.

Country Status (27)

Country	Link
US (2)	US20130252995A1 (es)
EP (1)	EP2646011B1 (es)
JP (1)	JP2014508717A (es)
KR (1)	KR20140035319A (es)
CN (1)	CN103298462A (es)
AR (2)	AR084093A1 (es)
AU (3)	AU2011336298B2 (es)
BR (1)	BR112013015957B1 (es)
CA (1)	CA2819003A1 (es)
CL (1)	CL2013001565A1 (es)
CY (1)	CY1119560T1 (es)
DK (1)	DK2646011T3 (es)
ES (1)	ES2647232T3 (es)
HR (1)	HRP20171678T1 (es)
HU (1)	HUE034641T2 (es)
IL (1)	IL226483A0 (es)
LT (1)	LT2646011T (es)
MX (1)	MX350304B (es)
NO (1)	NO2646011T3 (es)
PL (1)	PL2646011T3 (es)
PT (1)	PT2646011T (es)
RS (1)	RS56548B1 (es)
RU (1)	RU2620913C2 (es)
SI (1)	SI2646011T1 (es)
SM (1)	SMT201700537T1 (es)
TW (2)	TWI536986B (es)
WO (1)	WO2012075453A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2639579T3 (es)	2003-04-29	2017-10-27	Orexigen Therapeutics, Inc.	Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
JP5180092B2 (ja)	2005-11-22	2013-04-10	オレキシジェン・セラピューティクス・インコーポレーテッド	インスリン感受性を増すための組成物および方法
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
CN101573103A (zh)	2006-11-09	2009-11-04	奥雷西根治疗公司	用于施用重量减轻药物的单位剂量包装和方法
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
KR20120124423A (ko)	2010-01-11	2012-11-13	오렉시젠 세러퓨틱스 인크.	주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
RS67076B1 (sr)	2012-06-06	2025-08-29	Nalpropion Pharmaceuticals Llc	Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2197250C2 (ru) *	2000-10-30	2003-01-27	Соколовский Сергей Ростиславович	Способ лечения наркоманий
ES2639579T3 (es)	2003-04-29	2017-10-27	Orexigen Therapeutics, Inc.	Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
US20070099947A1 (en) *	2005-11-03	2007-05-03	Alkermes, Inc.	Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
CN101573103A (zh)	2006-11-09	2009-11-04	奥雷西根治疗公司	用于施用重量减轻药物的单位剂量包装和方法
AR063959A1 (es)	2006-11-09	2009-03-04	Orexigen Therapeutics Inc	Formulaciones farmaceuticas en capas
GB2447949B (en) *	2007-03-29	2010-03-31	Renasci Consultancy Ltd	A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) *	2007-09-13	2009-03-19	Sanfilippo Louis C	Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
CA2709861A1 (en) *	2007-12-20	2009-07-02	Neurosearch A/S	Pharmaceutical compositions
CA2817071C (en) *	2010-11-08	2018-04-24	Omeros Corporation	Treatment of addiction and impulse-control disorders using pde7 inhibitors

2011
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en not_active Ceased
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/en unknown
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Withdrawn
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 SM SM20170537T patent/SMT201700537T1/it unknown
- 2011-12-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown

Also Published As

Publication number	Publication date
DK2646011T3 (da)	2017-11-20
CN103298462A (zh)	2013-09-11
IL226483A0 (en)	2013-07-31
TW201735912A (zh)	2017-10-16
CA2819003A1 (en)	2012-06-07
MX350304B (es)	2017-09-04
TWI536986B (zh)	2016-06-11
WO2012075453A1 (en)	2012-06-07
HRP20171678T1 (hr)	2017-12-15
US20210283126A1 (en)	2021-09-16
LT2646011T (lt)	2017-11-10
MX2013006070A (es)	2013-07-29
BR112013015957B1 (pt)	2021-07-20
ES2647232T3 (es)	2017-12-20
PT2646011T (pt)	2017-11-17
BR112013015957A2 (pt)	2019-10-29
EP2646011A1 (en)	2013-10-09
RU2013127420A (ru)	2015-01-10
RU2620913C2 (ru)	2017-05-30
KR20140035319A (ko)	2014-03-21
JP2014508717A (ja)	2014-04-10
HUE034641T2 (en)	2018-02-28
PL2646011T3 (pl)	2018-01-31
EP2646011B1 (en)	2017-08-16
US20130252995A1 (en)	2013-09-26
EP2646011A4 (en)	2014-04-23
AR084093A1 (es)	2013-04-17
TW201228659A (en)	2012-07-16
AU2018203921A1 (en)	2018-06-21
SI2646011T1 (en)	2018-01-31
SMT201700537T1 (it)	2018-01-11
AU2017202793B2 (en)	2018-03-08
RS56548B1 (sr)	2018-02-28
AU2011336298A1 (en)	2013-07-11
CY1119560T1 (el)	2018-03-07
NO2646011T3 (es)	2018-01-13
AU2017202793A1 (en)	2017-05-18
AU2011336298B2 (en)	2017-03-02
AR124497A2 (es)	2023-04-05

Similar Documents

Publication	Publication Date	Title
CL2013001565A1 (es)	2014-04-04	Metodo para tratar la ingesta excesiva o comer compulsivamente, que comprende el uso de bupropion y naltrexona y la composicion farmaceutica que comprende a ambos compuestos.
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BR112014010179A8 (pt)	2018-01-09	composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI1008383A2 (pt)	2016-02-23	composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BR112015031475A2 (pt)	2017-07-25	composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BR112014011671A2 (pt)	2017-05-30	composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0912348A2 (pt)	2015-10-13	composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BR112012029227A2 (pt)	2016-11-29	processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto
BR112012022879A2 (pt)	2016-06-14	composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0718587A2 (pt)	2014-03-11	Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo
CL2011001331A1 (es)	2011-08-26	Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0916649A2 (pt)	2015-08-04	Composto, composição, uso de um composto, e, método para exterminar ou inibir o crescimento de uma espécie de plasmodium.